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ABSTRACT 27 
Background: Nanoduct™is a simple and practical sweat analysis system measuring conductivity in situ. 28 
It requires only three microlitres of sweat, making it especially applicable to newborns. 29 
Methods: We measured conductivity in 260 healthy term infants at the age of four days, and again at 30 
four weeks to determine the proportion of successful tests, test duration, and normal values for sweat 31 
conductivity in newborns. 32 
Results: Sufficient sweat was collected in 159/260 of four-day olds (61%), and in 225/239 of four-week 33 
olds (94%). Mean (sd) test duration was 27 (5) and 25 (5) min. Mean (sd, range) conductivity was 53 34 
mmol/l (16, 8–114) at age four days, and 36 (9, 12–64) at four weeks. 35 
Conclusions: Determination of sweat conductivity using Nanoduct™ cannot be recommended for 36 
four-day old newborns. However, at the age of four weeks the success rate is high (94%), and 37 
conductivity values at that age are comparable to older healthy children.  38 
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INTRODUCTION 39 
The sweat test is a key component for establishing a diagnosis of cystic fibrosis (CF) in infants with a 40 
positive result in newborn screening (NBS) 1.2. Collecting sufficient sweat for analysis is a challenge in 41 
small infants and some guidelines recommend delaying the test until the infant is more than two 42 
weeks of age or weighs more than 3 kg 3-5. Although for infants below three months of age test failure 43 
rates of up to 40% have been reported 6-10, North American recommendations aim for a failure rate of 44 
10% or less for sweat tests in NBS programs 2,6. 45 
Since the invention of the sweat test based on the pad method by Gibson and Cooke 60 years ago 11,12, 46 
sweat testing has evolved. The nowadays widely accepted Macroduct™ collection system needs 15 μl 47 
of sweat to analyze chloride concentration 2-4, while the sweat flow sensor of the Nanoduct™ sweat 48 
test system requires only 3 μl. This makes it especially applicable to newborns. However, it does only 49 
measure conductivity 13. 50 
Studies using Nanoduct™discriminated well between children with and without CF 13-17. This is also 51 
true for other sweat tests that measure conductivity instead of chloride concentration, for instance 52 
the Sweat-Check™ 18-22. Despite this, the European practice guidelines for neonatal screening and the 53 
US guidelines for diagnosis of CF do not recommend measuring sweat conductivity to diagnose CF 1,2. 54 
This study assessed the feasibility of sweat testing with the Nanoduct™ system in healthy newborns 55 
at the age of four days and four weeks, by determining the duration of the tests and the proportion 56 
of tests that were successful. We also wanted to determine the normal values of sweat conductivity 57 
for Nanoduct™ in this age group.   58 
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METHODS 59 
Subject and study design 60 
We conducted this single-center study from June 2013 to December 2014 with 260 healthy term 61 
infants born in the maternity unit of the Department of Gynaecology at the Cantonal Hospital St. 62 
Gallen in Switzerland. Each infant was tested twice with the Nanoduct™ (Wescor, Utah, USA) sweat 63 
system, at age 3–4 days and 3–4 weeks. We chose these age groups because in Switzerland NBS with 64 
the Guthrie test is performed at the age of 3–4 days, before infants leave the birth clinic 23,24. When 65 
they are 3–4 weeks old, children with a positive NBS result are recalled to a CF center for sweat testing. 66 
We asked all parents of healthy infants born in the hospital during this period to participate, except 67 
those whose infants were born prematurely (gestational age b37 weeks), had a birth weight below 68 
3000 g, or were sick, presenting symptoms such as oedema, hyperbilirubinemia, signs of dysmaturity, 69 
malnourishment, or a systemic disease. We also excluded children whose parents did not speak 70 
German, and all those who were discharged on a weekend. 71 
 72 
Nanoduct™ sweat test analysis system 73 
The Nanoduct™ sweat test is a micro-flow conductometric device, which induces and analyzes the 74 
conductivity of sweat in situ while attached to a patient. The procedure is described in detail 75 
elsewhere 13,20. In brief, iontopheresis using small Pilogel™ iontophoretic discs and direct current 76 
supplied by the Nanoduct™ inducer/analyzer is followed by a continuous-flow analysis of sweat 77 
conductivity using a conductivity sensor. The continuous-flow principle allows display of the initial 78 
sweat rate in grams per square meter of skin surface per minute, which is important in accepting sweat 79 
test results (valid results: ≥1 g/m2/min). Its continuous sweat flow sensor requires only 3 μl of sweat. 80 
The value of conductivity is expressed as mmol/l eq NaCl. This is not equal to a quantitative chloride 81 
measurement; its displayed equivalent is approximately 20 mmol/l higher than the sweat chloride 82 
concentration because of additional anions such as lactate and bicarbonate 18,19,21. 83 
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The sweat tests at the age of four days were carried out in the Department of Gynaecology of the 84 
Cantonal Hospital St. Gallen by two trained and experienced persons (Agnieszka Mazur and a research 85 
nurse). The sweat tests at the age of four weeks were performed at infants' homes or in the Children's 86 
Hospital in St. Gallen by the same two persons. The Nanoduct™ device was placed on a forearm or a 87 
leg. The sweat test was considered valid (that is, a successful test) if the sweat rate was ≥1 g/m2/min, 88 
and as not valid if the sweat rate was lower (b1 g/m2/min) or zero (no sweat rate displayed on 89 
Nanoduct™). 90 
The parents were told by the technician that the test results needed to be interpreted by the doctor, 91 
and were then informed by the investigator after the end of the two tests only if the result was 92 
regarded as ambiguous or not normal. If the second sweat test at the age of 4 weeks was above an 93 
upper limit of 60 mmol/l, we offered the parents another sweat test at the Children's Hospital, 94 
followed by a chloride measurement using the Macroduct™ method, if the conductivity value was still 95 
elevated. 96 
 97 
Statistical analysis 98 
We calculated the proportion of successful tests as the number of tests with valid results divided by 99 
the total number of tests performed. We compared the proportion of successful tests across quintiles 100 
of body weight at the day of the test, and across quintiles of weight loss between birth and the test 101 
day, in percent of birth weight, using tests for trend to assess statistical significance. We checked the 102 
distribution of quantitative data (duration of tests, conductivity) using histograms, Q–Q plots, and 103 
Shapiro–Wilk and Shapiro–Francia tests for normality. Since data were normally distributed, we 104 
described sweat conductivity (mmol/l) and test duration (minutes) as mean values and standard 105 
deviations (sd), and determined 95% (99%) reference intervals for sweat conductivity as the mean ± 2 106 
(± 3) standard deviations. For infants with paired data, we compared agreement with a Bland Altman 107 
plot, displaying the mean of the two values on the x axis versus the difference between the two 108 
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measurements on the y axis.We analyzed the data using STATA version 13.1 (StataCorp. 2005. Stata 109 
Statistical Software: Release 13.1 StataCorp LP, College Station, TX, USA). 110 
 111 
RESULTS 112 
Between July 1, 2013 and Dec 31, 2014, 2231 infants were born in the maternity unit in St. Gallen. Of 113 
these, 366 were excluded because of preterm birth, 707 because of low birth weight and 898 for 114 
different reasons (discharge at weekends, parent's insufficient knowledge of the German, clinical 115 
symptoms such as hyperbilirubinemia, or no parental consent). None of the children born in this unit 116 
had a positive CF-NBS result . Parents of 260 newborns agreed to participate (Table 1). In total, 239 117 
infants had two sweat tests (Table 2). Twenty-one infants were lost to follow-up at four weeks, twelve 118 
due to parental refusal, six due to no answer to repeated phone calls, and three because of 119 
unavailability of the sweat test equipment on the test day. The time needed to perform the sweat test 120 
was on average 27 min (5–40, sd 5 min) at the age of 4 days, and 25 min (14–40, sd 5 min) at the age 121 
of 4 weeks. 122 
The proportion of successfully conducted sweat tests was 61% at age 4 days, and 94% in four-week 123 
olds (Table 2). At age four days, 159 of 260 infants (61%) produced enough sweat (≥3 μl), while 23 124 
(9%) had an insufficient quantity and 78 (30%) produced no sweat at all (Table 2). The proportion of 125 
successful tests was positively associated with body weight, varying from 49% for those in the lowest 126 
quintile (2.8–2.9 kg) to 69% in those in the highest (3.7–4.6 kg, p = 0.024). The proportion of successful 127 
tests was also associated with weight loss: it was lowest (48%) in those infants who had lost most 128 
weight between birth and the day of measurement (p = 0.034). At age four weeks, 225 of 239 infants 129 
(94%) produced sufficient sweat. Five children (2%) had insufficient quantities and nine (4%) had no 130 
sweat. At this age, the proportion of successful tests was >90% across all quintiles of body weight, 131 
with no clear trend (p = 0.221). 132 
At four weeks of age the sweat conductivity values were normally distributed (Table 3 and Fig. 1). The 133 
mean value was 35 mmol/l (range 12–64) and the upper limit of the 95% reference interval (mean + 134 
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1.96 sd) was 53 mmol/l. Two children (2%) had a conductivity value above the threshold of 60 mmol/l, 135 
and were invited for another sweat test at the Children's Hospital; one mother refused to come and 136 
the other child had a normal sweat test. The Bland Altman plot illustrates that the 2nd measurements 137 
were in average 18 mmol/l lower, with outliers at the two extremes, reflecting measurements that 138 
were technically unsatisfactory at one of the two time points (online Fig. 1). 139 
 140 
DISCUSSION 141 
This is the first study to generate normal reference values for conductivity using the Nanoduct™ sweat 142 
test in an unselected group of healthy newborns. Its main strength is the relatively large and 143 
homogeneous population of healthy newborns and their young age. The study included only children 144 
who cleared the CF-NBS program as healthy, non-CF children, but because we did no genetic testing 145 
in these children we cannot exclude the possibility that some children were healthy CF-carriers or had 146 
mild (‘atypical’) forms of CF 23. Based on an incidence of CF in Switzerland of about 1 in 3000 23,24, we 147 
expect that our study population could include about five CF carriers. Yet even if conductivity were 148 
slightly higher in carriers, this low number would not have strongly influenced our results. All sweat 149 
tests were performed strictly according to guidelines, with the same equipment, by two trained testers 150 
in a single center, which minimizes the probability of differences in test results caused by variations in 151 
material or procedures. However, the very fact that this was a carefully conducted, single-center study 152 
that excluded low birth weight and sick infants might reduce the generalizability of the results. 153 
Although we included twice as many data points than generally requested as minimum number to 154 
determine reference values (120) 25, a larger sample would have been even more informative. 155 
We are aware of only six other studies that have investigated the performance of the Nanoduct™ 156 
sweat test system and reported values in the normal range for conductivity (Table 4). None of the 157 
studies included children who could be considered totally healthy or normal: four analyzed data of 158 
patients with chronic respiratory symptoms referred to outpatient clinics for exclusion of CF 13-15,26, 159 
and two reported on sweat tests in neonates with a positive NBS result 16,17. Still, our conductivity 160 
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results for healthy four-week old infants are comparable with these studies of older infants, children, 161 
and adults, which all reported mean values between 30 and 42 mmol/l. When comparing our results 162 
with reference values for sweat chloride in 5–6 week-old infants using the Macroduct™ collection 163 
system (median 12 mmol/l (IQR 9–15) 27, our equivalent conductivity values at four weeks (median 35 164 
mmol/l, IQR 30–41) are on average 23 mmol/l higher (exactly the same value which was found by 165 
Mastella et al. 21 in his healthy control group), but the distribution approximated a normal distribution 166 
in both studies. 167 
The proportion of successfully conducted sweat tests in our study was low (61%) at age 4 days, but 168 
excellent (94%) in four-week old. This is comparable to our previous multicenterstudy, where it was 169 
48% in newborns (55% in term, 31% in preterm), 90% in older infants, and 95% in children and adults 170 
14. Our results also confirm earlier studies focusing on the Macroduct™sweat test, which reported 171 
lower proportions of successful tests in very young infants. For example, the Massachusetts NBS 172 
program found that the percentage of sweat tests interpreted as “quantity not sufficient” (QNS) was 173 
17% at the age of 2 weeks, 12% at 3 weeks, 8% at 4 weeks, and 5% at 5 weeks 10. 174 
In studies that have compared the Macroduct™directly with the Nanoduct™, Nanoduct™ usually 175 
performed better. For example, the Vernooij-van Langen et al. study reported a difference in QNS 176 
rates of 7% for Nanoduct™ tests, and 22% for Macroduct™ tests (p = 0.002) 17, while the Barben et al. 177 
study reported QNS results of 3% for Nanoduct™ tests and 15% for Macroduct tests (p = 0.003) 13. 178 
What do these results mean? The current guidelines for CF-NBS in Europe and the guidelines for CF 179 
diagnosis in all age groups do not recommend conductivity measurements for the diagnosis of CF in 180 
newborns 1,2. Our data suggest that at an age of four weeks, if not before, the Nanoduct™ sweat test 181 
method could be a useful tool for diagnosing CF in NBS programs, using 50 mmol/l as an upper limit, 182 
the threshold recommended by the CFF for performing confirmatory sweat chloride measurements 4. 183 
Twelve of the 225 children in our study (5%) had a conductivity above the threshold of 50 mmol/l, and 184 
2 (2%) above 60 mmol/l, the suggested upper normal value by the manufacturer 13. 185 
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In CF-NBS programs, a definite diagnosis should be made as quickly as possible to reduce parental 186 
anxiety 28. We believe that Nanoduct™ is a good tool for excluding CF at the age of 3–4 weeks, as the 187 
success rate is high and the results are available within half an hour. In contrast, chloride 188 
measurements need hours to get a result, and the collection in newborns is challenging due to the 189 
higher quantity of sweat (15 μl), and thus high failure rates infants 6-9. In Switzerland, children with a 190 
positive CF-NBS result are recalled for a sweat test at the age of 3–4 weeks. The failure rate of the 191 
Nanoduct™ at this age (6%) is acceptable according to the current recommendations, which aim for 192 
less than 10% 3-6. Within the Swiss CF-NBS program, we use the Nanoduct™ and the Macroduct™ test 193 
in parallel since 2011, to reduce delays for parents of infants where theMacroduct™is not successful 194 
13,14,17. The Nanoduct™test system has the potential disadvantage that parents can spot the results, 195 
because conductivity is displayed on the screen of the apparatus attached to the child. Our lab 196 
technicians do not report any result. Parents who ask the lab technician are told that the data quality 197 
needs to be checked by the physician before results can be interpreted. In clinical routine in the Swiss 198 
neonatal screening, a CF specialist is called as soon as the Nanoduct™result is available and 199 
informs the parents. 200 
This study is the first to provide normal ranges for sweat conductivity using the Nanoduct™ sweat test 201 
system for healthy newborns. Determination of sweat conductivity using Nanoduct™ cannot be 202 
recommended for four-day old newborns. However, at the age of four weeks the success rate is high 203 
(94%), and conductivity values at that age are comparable to those reported for older healthy children. 204 
The generated reference range improves the available evidence on the validity of this method. This 205 
suggests that Nanoduct™ might be a suitable sweat test for NBS programs in which children are seen 206 
in the first months of life. 207 
Part of this work has been presented at the European Cystic Fibrosis Conference in Brussels, Belgium, 208 
June 10–13, 2015. 209 
 210 
 211 
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TABLES 292 
Table 1 293 
Characteristics of the study population, and duration of the Nanoduct™ sweat test in newborns at the 294 
age of four days and four weeks (N = 260). aMeasurement available for 259 out of 260 infants. 295 
 296 
 297 
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Table 2  298 
Proportion of successfully completed Nanoduct™ tests (success rate) in healthy infants at the age of four days and four weeks. Abbreviations: CI, confidence 299 
interval; n, number of children; n/a, not applicable.  a Values in quintiles overlap due to rounding. 300 
 301 
  302 
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Table 3 303 
Normal values of sweat conductivity (mmol/l) in healthy infants at the age of four days and four weeks 304 
 305 
  306 
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Table 4 307 
Results of studies looking at success rate and conductivity of the Nanoduct™ sweat test 308 
 309 
 310 
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FIGURES 311 
Figure 1  312 
Distribution of normal conductivity values (histogram) at the age of four days and four weeks. 313 
a. Sweat test four days after birth: normal values (mean ± 2 sd) indicated by red bar b. Sweat test four 314 
weeks after birth: normal values (mean ± 2 sd) indicated by red bar 315 
 316 
